Spyre Therapeutics presents preclinical and clinical data on three IBD antibodies at UEGW 2026
Spyre Therapeutics disclosed preclinical mouse data showing additive efficacy of its three IBD antibodies—SPY001, SPY002 and SPY003—at United European Gastroenterology Week in Barcelona. The same antibodies were also presented in clinical proof‑of‑concept data, and are being evaluated as monotherapies and pairwise combinations in the Phase 2 SKYLINE platform trial. Silvio Danese, chair of the SKYLINE trial steering committee, said the company is eager to see combination results next year.
Why it matters
The company’s progress signals potential differentiation in the IBD market, and upcoming SKYLINE combination readouts next year could affect Spyre’s valuation and investor sentiment.
Key facts
- 1Spyre presented data at United European Gastroenterology Week 2026 in Barcelona on Oct. 18 2026. stocktitan.net
- 2The presentations covered three antibodies: SPY001 (anti‑α4β7), SPY002 (anti‑TL1A) and SPY003 (anti‑IL‑23). stocktitan.net
- 3Preclinical mouse studies showed additive efficacy when the antibodies were combined. stocktitan.net
- 4The antibodies are being tested as monotherapies and pairwise combinations in the SKYLINE Phase 2 platform trial. investing.com
- 5Silvio Danese, M.D., Ph.D., served as presenter for the oral session and is chair of the SKYLINE trial steering committee. stocktitan.net
- 6An oral presentation was scheduled for Sunday, Oct. 18, 15:30‑15:40 CEST, and a moderated poster for Monday, Oct. 19, 16:06‑16:12 CEST. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.